Allphavax

AlphaVax is a privately held, clinical-stage biopharmaceutical company developing vaccine candidates for infectious diseases, cancer immunotherapy, and biodefense applications. The company is built around its proprietary alphavaccine RNA particle vector platform, a self-replicating RNA replicon system derived from attenuated Venezuelan equine encephalitis virus strains. AlphaVax has reported a portfolio of seven vaccine candidates, with four programs evaluated across five Phase 1 clinical trials, including candidates targeting cytomegalovirus, influenza A, HIV-1, and prostate cancer. The company has also advanced immunotherapeutic cancer vaccine studies in breast, gastrointestinal, and colon cancers. Its business model includes internal development in oncology and out-licensing or partnering its platform for selected infectious disease and veterinary applications.